Acute Exacerbation of COPD

Acute Exacerbation of Bronchiectasis

Acute Exacerbation of Asthma

Interstitial Lung Disease

Neuromuscular Diseases

Obesity Hypoventilation Syndrome

Acute Respiratory Failure

Service de Pneumologie et Réanimation Médicale, Groupe Hospitalier Pitié Salpêtrière Paris, France

Outcomes of RV Dysfunction in Acute Exacerbation of Chronic Respiratory Diseases

Prevalence of Right Ventricular Dysfunction in Acute Exacerbation of Chronic Respiratory Diseases and Its Impact on Outcomes

Duration of non-invasive ventilation and/or mechanical ventilation

Association pour le Développement et l'Organisation de la Recherche en Pneumologie et sur le Sommeil

3 g/d soy oil: corn oil (50:50 ratio) + placebo powder

Chronic Obstructive Pulmonary Disease

For Fish oil and Placebo oil, treatment will be provided in capsules.Each group will receive dose distributed to 3 capsules per day. Participants will be instructed to take all capsules with morning meal. . For HMB and a placebo powder, product will be delivered as powder taken with water or non-carbonated beverage (like juice). Product will be provided in 2 sachets/day. One sachet should be consumed with breakfast and the other prior to bedtime (approx. 10pm).

Capsule + Powder supplementation

labeled amino acids L-Phenylalanine (ring-13C6), L-Tyrosine (ring-D4), and tau-Methylhistidine will be infused as a single injection. Subsequently, the catheter will be used for arterialized venous blood samples (3 ml) drawn multiple through the day

stable tracer infusion

Texas A&M University-CTRAL

Fish Oil and HMB Supplementation in COPD

Effects of Low Dose of Fish Oil (EPA+DHA) vs. Combined EPA+DHA and HMB Supplementation on Protein Metabolism, Muscle Mass and Functional Capacity in Moderate to Severe COPD

whole body protein synthesis and myofibrillar protein breakdown measured by labeled amino acids on each study day via blood drawn at time 4, 10, 15, 20, 30, 40, 60, 120, 180, 240 minutes of infusion

Body composition as measured by Dual-Energy X-ray Absorptiometry

Micro-respiratory pressure meter to measure maximum inspiratory and expiratory pressure

walk a predetermined loop of 69.77 meters (228.89 feet) at self-selected pace for six minutes

blood sample will be taken to measure c-reactive protein levels

Oxygen consumption and carbon dioxide production will be calculated from the airflow in a transparent plastic (Plexiglas) hood to determine concentration differences between inhaled and exhaled air

Marielle PKJ Engelen, PhD

Associate Professor

Texas A&M University

Male or female current or former smokers. Forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) >0.7. FVC >lower limit of normal (LLN). Modified Medical Research Council (mMRC) dyspnea score = 0.

Male or female current or former smokers. FEV1/FVC >0.7. FVC >LLN. mMRC dyspnea score ≥1.

Male or female current or former smokers. FEV1/FVC ≤0.7. FEV1 >80% of predicted value. mMRC dyspnea score =0.

Male or female current or former smokers. FEV1/FVC ≤0.7. FEV1 >80% of predicted value. mMRC dyspnea score ≥1.

Copd

Respiratory Department; Hospital Clinico Universidad Catolica

Searching Clinical Chronic Obstructive Pulmonary Disease Onset

The Boundaries of Mild Chronic Obstructive Pulmonary Disease: Searching Clinical COPD Onset

Emphysema will be quantitated using the percentage of low-attenuation units less than −950 Hounsfield units (HU) using open source software (www.Slicer.org).

Single-slice airway measurements will be collected in the apical bronchus of the right upper lobe and the right lower lobe posterior basal bronchus. Measurements will be performed in the 3rd, 4th, and 5th airway generation.

The cross-sectional area of the right thigh muscle will be measured at halfway between the pubic symphysis and the inferior condyle of the femur, in the surface area of the tissue with a density of 40 to 100 HU. This range of density corresponds to the density of muscle tissue.

Spirometry, single-breath DLCO, and plethysmographic lung volume assessment will be performed

Transthoracic stress echocardiography will be performed with a VIVID-7 echocardiography system and echo cardiac stress table, with electrical adjustable slope for an optimal position of the heart. Function in each segment of the left ventricle (LV) will be graded at rest and with stress as normal or hyperdynamic, hypokinetic, akinetic, dyskinetic, or aneurysmal. In addition to the evaluation of segmental function, the global LV response to stress be assessed. Diastolic function will be analysed at rest, and systolic function at rest and end exercise

A triaxial accelerometer will be used. This accelerometer measures activity counts and vector magnitude, energy expenditure, steps taken, physical activity intensity, subject position, and ambient light levels. We will retrieve, collect and study three physical activity (PA) outcomes: step count (i.e. movement); spent physical activity time per day (i.e., moderate or vigorous), and PA level (i.e., activity related energy expenditure).

A symptom-limited incremental cycle exercise test will be conducted to measure the maximal workload. A constant work rate cycle endurance test will be performed afterwards.

Pontificia Universidad Catolica de Chile

All patients underwent extensive evaluation:
- Body composition, Diabetes; dyslipidemia, hemoconcentration, hypertension, exercise capacity: 6-Minute Walk test procedure, renal function, inflammatory markers, cause and place of death, time tracking concentrator, quality of life and pulmonary Function.

Chronic Obstructive Pulmonary Disease and Allied Conditions

The Global Initiative for Chronic Obstructive Lung Disease (GOLD) works with health care professionals and public health officials to raise awareness of Chronic Obstructive Pulmonary Disease (COPD) and to improve prevention and treatment of this lung di

Predictors of Mortality in Patients With Advanced Lung Disease in Home Oxygen Therapy

Evaluate the results of evaluations carried out in patients who died and had advanced lung disease diagnosis in use of home oxygen, compared to patients who did not die and the normal population

Assess the amount of oxygen that was used by patients during treatment indication and measurement of variable

Measure the quality of life of these patients and compared with the normal population and patients who died and had survival for longer period

Search the causes of death of these patients and the place to compare with the current epidemiology and relate to the main disease

bronchiectasis/obesitat

Outcomes of RV Dysfunction in Acute Exacerbation of Chronic Respiratory Diseases

Fish Oil and HMB Supplementation in COPD

Searching Clinical Chronic Obstructive Pulmonary Disease Onset

Predictors of Mortality in Patients With Advanced Lung Disease in Home Oxygen Therapy

La base de dades d’herbes medicinals més completa avalada per la ciència